Tirzepatide

a.k.a. GIP/GLP-1 Dual Agonist · LY3298176 · Mounjaro · Zepbound

Dual GIP/GLP-1 agonist for advanced metabolic research

💉 Subcutaneous Injection

Purity

≥98%

Form

Lyophilized Powder

Mol. Weight

4813.45 g/mol

Storage

-20°C

Research Applications

Fat LossAnti-Aging

Select Size

Quantity

Total

$60.00

Research Use Only · Not for human consumption. Intended for in vitro laboratory and research applications.

Description

Tirzepatide is a dual GIP and GLP-1 receptor agonist that has shown remarkable efficacy in clinical trials. It's FDA-approved for diabetes (Mounjaro) and weight management (Zepbound).

Mechanism of Action

Tirzepatide activates both GIP and GLP-1 receptors, providing complementary mechanisms for metabolic regulation. The dual action affects appetite, gastric emptying, insulin secretion, and fat cell metabolism.

Specifications

Purity: ≥98%
Form: Lyophilized Powder
Molecular Weight: 4813.45 g/mol
Storage: -20°C

Related Peptides

View All

Weight Management

Retatrutide

Next-gen triple agonist (GLP-1/GIP/Glucagon) for metabolic research

From $120

Weight Management

Semaglutide

The original GLP-1 agonist for metabolic research

From $30

Weight Management

Cagrilintide

Long-acting amylin analog for combination therapy research

From $40

$60.00

10mg (Single Vial) × 1